Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Reproductive Toxicology (Elmsford, N.Y.)|June 19, 2026
Thyroid dysregulation underlies altered ovarian cyclicity in rats exposed to PF-06835919, a ketohexokinase inhibitorSarah N Campion, Christopher J Bowman, Chris Houle, et al.
The Medical Journal of Australia|June 11, 2026
The Management of Withdrawal From Alcohol and Other Drugs in Australian Custodial Settings: A Consensus StatementGrace FitzGerald, Jocelyn Chan, Jon Cook, et al.
The Medical Journal of Australia|March 2, 2025
National consensus statement on opioid agonist treatment in custodial settingsJocelyn Chan, Jon Cook, Michael Curtis, et al.
Journal of General Internal Medicine|October 27, 2021
Medicare Claim-Based National Institutes of Health Stroke Scale to Predict 30-Day Mortality and Hospital ReadmissionAmit Kumar, Indrakshi Roy, Pamela R Bosch, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 31, 2022
Early Drug-Induced Liver Injury Risk Screening: "Free," as Good as It GetsMatthew T Martin, Petra Koza-Taylor, Li Di, et al.
Neurotoxicology|February 5, 2024
Absence of functional deficits in rats following systemic administration of an AAV9 vector despite moderate peripheral nerve and dorsal root ganglia findings: A clinically silent peripheral neuropathyCheryl Tyszkiewicz, Seo-Kyoung Hwang, Jamie K DaSilva, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|January 22, 2021
Experiments in the EpiDerm 3D Skin In Vitro Model and Minipigs In Vivo Indicate Comparatively Lower In Vivo Skin Sensitivity of Topically Applied Aneugenic CompoundsMaik Schuler, Lindsay Tomlinson, Michael Homiski, et al.
Drug and Alcohol Review|October 7, 2024
Provider costs of treating opioid dependence with extended-release buprenorphine in AustraliaStella Settumba, Jeyran Shahbazi, Marianne Byrne, et al.
The International Journal on Drug Policy|November 4, 2021
Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependenceMichael Farrell, Jeyran Shahbazi, Marianne Byrne, et al.
The International Journal on Drug Policy|March 24, 2024
96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trialMichael Farrell, Jeyran Shahbazi, Mark Chambers, et al.
Pageof 2